ArticleBMC nephrology2025
How does LAMB2 contribute to kidney disease? Insights from a pediatric case.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe present the case of an 11-year-old girl who has been followed for the past four years after the incidental discovery of asymptomatic microhematuria during school enrollment. CASE PRESENTATION: Over the course of follow-up, glomerular-origin microhematuria persisted, and mild proteinuria developed and persisted for over six months. This prompted the need for a kidney biopsy. Light microscopy revealed normal kidney tissue, and immunofluorescence findings were negative. However, electron microscopy demonstrated significant variation in glomerular basement membrane (GBM) thickness, with focal splitting. A diagnosis of Alport syndrome was initially suspected, but genetic testing for collagen IV mutations (COL4A3, COL4A4, COL4A5) did not support this diagnosis. Instead, a variant in the LAMB2 gene (c.5039 C > T, p.Ala1680Val) was identified. The variant has not been previously described in the literature but is listed in ClinVar as a variant is of uncertain significance (VUS) and may be associated with the GBM abnormalities observed, leading to the persistent hematuria and proteinuria. Over a one-year follow-up period, the patient has maintained normal renal function without significant proteinuria or hypertension, with only persistent microhematuria.
conclusionsGiven the uncertain long-term outcome and the potential impact of the LAMB2 variant on renal function, regular nephrological monitoring remains essential to detect and manage any progression to end-stage renal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.